Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia
Abstract Objective Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25...
Gespeichert in:
| Veröffentlicht in: | Journal of anxiety disorders 2009-04, Vol.23 (3), p.362-368 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368 |
|---|---|
| container_issue | 3 |
| container_start_page | 362 |
| container_title | Journal of anxiety disorders |
| container_volume | 23 |
| creator | Donahue, Christopher B Kushner, Matt G Thuras, Paul D Murphy, Tom G Van Demark, Joani B Adson, David E |
| description | Abstract Objective Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method Individuals with SAD ( N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking. |
| doi_str_mv | 10.1016/j.janxdis.2008.12.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66986046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0887618508002193</els_id><sourcerecordid>57279111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-3e8904391cbc1a3a1d5d62b20d1b0d1fcb478a345403aa703425aa1244d4b43d3</originalsourceid><addsrcrecordid>eNqFkkGP1SAUhRujcZ6jP0HDRnetXKDQbjSTyTiaTOJCXRMK1KHTBxXa92b-vTSvExM3k0BY8J1zL5xbFG8BV4CBfxyqQfl741JFMG4qIBXG7Fmxg0bQUjSteF7scNOIkkNTnxWvUhowBoG5eFmcQQu1EILviuNV31s9o9CjP4udnZqct-iQKjSNStsuoOBRtGkKPlk0BzQfAzq4OC9qRNPSjU6jNFl15_xvZO-nkJZMI-fzMu7gTOYSOrr5FqWg3Sq6DZ1Tr4sXfb6xb7bzvPj15ern5dfy5vv1t8uLm1Iz0c4ltU2LGW1BdxoUVWBqw0lHsIEu7153TDSKspphqpTAlJFaKSCMGdYxauh58eHkO8WQH5hmuXdJ23FU3oYlSc7bhmPGnwRrQUQLABmsT6COIaVoezlFt1fxQQKWazRykFs0co1GApE5mqx7txVYur01_1RbFhl4vwEqaTX2UXmdPR45ArkBzFejzyfO5n87OBtl0s56bY2LOUppgnuylU__OejReZeL3tkHm4awRJ9DkSBTFsgf6xytY4QbjAm0lP4FuvLFrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>57279111</pqid></control><display><type>article</type><title>Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia</title><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><creator>Donahue, Christopher B ; Kushner, Matt G ; Thuras, Paul D ; Murphy, Tom G ; Van Demark, Joani B ; Adson, David E</creator><creatorcontrib>Donahue, Christopher B ; Kushner, Matt G ; Thuras, Paul D ; Murphy, Tom G ; Van Demark, Joani B ; Adson, David E</creatorcontrib><description>Abstract Objective Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method Individuals with SAD ( N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.</description><identifier>ISSN: 0887-6185</identifier><identifier>EISSN: 1873-7897</identifier><identifier>DOI: 10.1016/j.janxdis.2008.12.004</identifier><identifier>PMID: 19157776</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Adult and adolescent clinical studies ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - therapeutic use ; Anxiety disorders. Neuroses ; Biological and medical sciences ; Depression - diagnosis ; Depression - psychology ; Diagnostic and Statistical Manual of Mental Disorders ; Dibenzothiazepines - administration & dosage ; Dibenzothiazepines - therapeutic use ; Disorders of Excessive Somnolence - diagnosis ; Double-Blind Method ; Drug Administration Schedule ; Drugs ; Female ; Heart rate ; Heart Rate - physiology ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Phobia ; Phobic Disorders - drug therapy ; Phobic Disorders - psychology ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Public speaking ; Quetiapine ; Quetiapine Fumarate ; Severity of Illness Index ; Social anxiety ; Social phobia ; Speech ; Surveys and Questionnaires ; User-Computer Interface ; Virtual reality ; Young Adult</subject><ispartof>Journal of anxiety disorders, 2009-04, Vol.23 (3), p.362-368</ispartof><rights>Elsevier Ltd</rights><rights>2008 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-3e8904391cbc1a3a1d5d62b20d1b0d1fcb478a345403aa703425aa1244d4b43d3</citedby><cites>FETCH-LOGICAL-c479t-3e8904391cbc1a3a1d5d62b20d1b0d1fcb478a345403aa703425aa1244d4b43d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.janxdis.2008.12.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,31000,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21279064$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19157776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Donahue, Christopher B</creatorcontrib><creatorcontrib>Kushner, Matt G</creatorcontrib><creatorcontrib>Thuras, Paul D</creatorcontrib><creatorcontrib>Murphy, Tom G</creatorcontrib><creatorcontrib>Van Demark, Joani B</creatorcontrib><creatorcontrib>Adson, David E</creatorcontrib><title>Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia</title><title>Journal of anxiety disorders</title><addtitle>J Anxiety Disord</addtitle><description>Abstract Objective Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method Individuals with SAD ( N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.</description><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Anxiety disorders. Neuroses</subject><subject>Biological and medical sciences</subject><subject>Depression - diagnosis</subject><subject>Depression - psychology</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Dibenzothiazepines - administration & dosage</subject><subject>Dibenzothiazepines - therapeutic use</subject><subject>Disorders of Excessive Somnolence - diagnosis</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drugs</subject><subject>Female</subject><subject>Heart rate</subject><subject>Heart Rate - physiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phobia</subject><subject>Phobic Disorders - drug therapy</subject><subject>Phobic Disorders - psychology</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Public speaking</subject><subject>Quetiapine</subject><subject>Quetiapine Fumarate</subject><subject>Severity of Illness Index</subject><subject>Social anxiety</subject><subject>Social phobia</subject><subject>Speech</subject><subject>Surveys and Questionnaires</subject><subject>User-Computer Interface</subject><subject>Virtual reality</subject><subject>Young Adult</subject><issn>0887-6185</issn><issn>1873-7897</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkkGP1SAUhRujcZ6jP0HDRnetXKDQbjSTyTiaTOJCXRMK1KHTBxXa92b-vTSvExM3k0BY8J1zL5xbFG8BV4CBfxyqQfl741JFMG4qIBXG7Fmxg0bQUjSteF7scNOIkkNTnxWvUhowBoG5eFmcQQu1EILviuNV31s9o9CjP4udnZqct-iQKjSNStsuoOBRtGkKPlk0BzQfAzq4OC9qRNPSjU6jNFl15_xvZO-nkJZMI-fzMu7gTOYSOrr5FqWg3Sq6DZ1Tr4sXfb6xb7bzvPj15ern5dfy5vv1t8uLm1Iz0c4ltU2LGW1BdxoUVWBqw0lHsIEu7153TDSKspphqpTAlJFaKSCMGdYxauh58eHkO8WQH5hmuXdJ23FU3oYlSc7bhmPGnwRrQUQLABmsT6COIaVoezlFt1fxQQKWazRykFs0co1GApE5mqx7txVYur01_1RbFhl4vwEqaTX2UXmdPR45ArkBzFejzyfO5n87OBtl0s56bY2LOUppgnuylU__OejReZeL3tkHm4awRJ9DkSBTFsgf6xytY4QbjAm0lP4FuvLFrA</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Donahue, Christopher B</creator><creator>Kushner, Matt G</creator><creator>Thuras, Paul D</creator><creator>Murphy, Tom G</creator><creator>Van Demark, Joani B</creator><creator>Adson, David E</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20090401</creationdate><title>Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia</title><author>Donahue, Christopher B ; Kushner, Matt G ; Thuras, Paul D ; Murphy, Tom G ; Van Demark, Joani B ; Adson, David E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-3e8904391cbc1a3a1d5d62b20d1b0d1fcb478a345403aa703425aa1244d4b43d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Anxiety disorders. Neuroses</topic><topic>Biological and medical sciences</topic><topic>Depression - diagnosis</topic><topic>Depression - psychology</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Dibenzothiazepines - administration & dosage</topic><topic>Dibenzothiazepines - therapeutic use</topic><topic>Disorders of Excessive Somnolence - diagnosis</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drugs</topic><topic>Female</topic><topic>Heart rate</topic><topic>Heart Rate - physiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phobia</topic><topic>Phobic Disorders - drug therapy</topic><topic>Phobic Disorders - psychology</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Public speaking</topic><topic>Quetiapine</topic><topic>Quetiapine Fumarate</topic><topic>Severity of Illness Index</topic><topic>Social anxiety</topic><topic>Social phobia</topic><topic>Speech</topic><topic>Surveys and Questionnaires</topic><topic>User-Computer Interface</topic><topic>Virtual reality</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Donahue, Christopher B</creatorcontrib><creatorcontrib>Kushner, Matt G</creatorcontrib><creatorcontrib>Thuras, Paul D</creatorcontrib><creatorcontrib>Murphy, Tom G</creatorcontrib><creatorcontrib>Van Demark, Joani B</creatorcontrib><creatorcontrib>Adson, David E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of anxiety disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Donahue, Christopher B</au><au>Kushner, Matt G</au><au>Thuras, Paul D</au><au>Murphy, Tom G</au><au>Van Demark, Joani B</au><au>Adson, David E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia</atitle><jtitle>Journal of anxiety disorders</jtitle><addtitle>J Anxiety Disord</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>23</volume><issue>3</issue><spage>362</spage><epage>368</epage><pages>362-368</pages><issn>0887-6185</issn><eissn>1873-7897</eissn><abstract>Abstract Objective Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method Individuals with SAD ( N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>19157776</pmid><doi>10.1016/j.janxdis.2008.12.004</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6185 |
| ispartof | Journal of anxiety disorders, 2009-04, Vol.23 (3), p.362-368 |
| issn | 0887-6185 1873-7897 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66986046 |
| source | MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier) |
| subjects | Adult and adolescent clinical studies Antipsychotic Agents - administration & dosage Antipsychotic Agents - therapeutic use Anxiety disorders. Neuroses Biological and medical sciences Depression - diagnosis Depression - psychology Diagnostic and Statistical Manual of Mental Disorders Dibenzothiazepines - administration & dosage Dibenzothiazepines - therapeutic use Disorders of Excessive Somnolence - diagnosis Double-Blind Method Drug Administration Schedule Drugs Female Heart rate Heart Rate - physiology Humans Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Phobia Phobic Disorders - drug therapy Phobic Disorders - psychology Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Public speaking Quetiapine Quetiapine Fumarate Severity of Illness Index Social anxiety Social phobia Speech Surveys and Questionnaires User-Computer Interface Virtual reality Young Adult |
| title | Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T02%3A29%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20quetiapine%20vs.%20placebo%20on%20response%20to%20two%20virtual%20public%20speaking%20exposures%20in%20individuals%20with%20social%20phobia&rft.jtitle=Journal%20of%20anxiety%20disorders&rft.au=Donahue,%20Christopher%20B&rft.date=2009-04-01&rft.volume=23&rft.issue=3&rft.spage=362&rft.epage=368&rft.pages=362-368&rft.issn=0887-6185&rft.eissn=1873-7897&rft_id=info:doi/10.1016/j.janxdis.2008.12.004&rft_dat=%3Cproquest_cross%3E57279111%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=57279111&rft_id=info:pmid/19157776&rft_els_id=1_s2_0_S0887618508002193&rfr_iscdi=true |